 "Aurobindo Pharma gets USFDA nod to market potassium chloride pills in US")
Aurobindo Pharma Ltd Friday said it has got the approval of the US Food and Drug Administration (USFDA) to make and market potassium chloride tablets of 600 mg and 750 mg for the US market.
The tablet, a generic version of Upsher-Smith's Klor-Con extended release tablets, would be launched next month, said a press release here.
The potassium chloride tablets are for treating hypokalemia, a condition wherein there is a drop in the potassium-level in the blood.
The drug has an estimated market size of USD 60 million for 12 months ending October 2018, the release said quoting market reports.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app